Physician profile
William E Johnson
NPI 1396763959
$2,665.27
in general payments reported to CMS, 2019-2025
29 companies · $271 in 2025
The $271 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $523 · 2020: $424 · 2021: $318 · 2022: $506 · 2023: $357 · 2024: $266 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $894.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $893.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $401.57 | 2019-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $350.30 | 2020-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $266.11 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Abbvie INC. | $243.64 | 2021-2023 | |
| Alexion Pharmaceuticals, INC. | $157.96 | 2019-2025 | Ultomiris |
| Astrazeneca Pharmaceuticals Lp | $136.51 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $134.52 | 2019-2023 | Camzyos |
| Allergan, INC. | $127.46 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $100.04 | 2019 | |
| Vifor Pharma, INC. | $96.06 | 2019-2020 | |
| Pfizer INC. | $87.21 | 2021-2022 | |
| Inari Medical, INC. | $84.79 | 2022-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.75 | 2023-2025 | Jardiance |
| Gilead Sciences, INC. | $63.01 | 2022-2025 | Veklury |
| Argenx US, INC. | $49.91 | 2023 | Vyvgart |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $29.57 | 2025 | Flowtriever |
| Tetraphase Pharmaceuticals, INC. | $29.04 | 2019 | |
| Insmed, INC. | $27.26 | 2025 | Arikayce |
| Abiomed | $26.56 | 2025 | |
| Recor Medical INC | $25.11 | 2024 | Paradise Renal Denervation System |
| Ucb, INC. | $24.87 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.83 | 2019 | |
| Seagen INC. | $19.92 | 2023 | Padcev |
| Melinta Therapeutics, LLC | $18.67 | 2021 | |
| Alkermes, INC. | $18.47 | 2019 | |
| Vanda Pharmaceuticals INC. | $18.33 | 2019 | |
| Urgo Medical North America, LLC | $16.06 | 2024 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Novo Nordisk INC | $12.44 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $11.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.